Aims: The prognostic impact of in-stent restenosis (ISR) detected upon routine follow-up coronary angiography (RFU-CAG) after percutaneous coronary intervention (PCI) has been unclear. The aim of our study was to compare the clinical outcomes after RFU-CAG between patients with and without ISR detected upon RFU-CAG. Methods and results: A total of 824 patients who underwent PCI and RFU-CAG were analysed. Patients were divided into two groups: those with ISR (n=112) and those without (n=712). Outcomes were compared between patients with ISR and those without detected upon RFU-CAG. The study patients were followed up for a median of 1,323 (709 to 2,130) days. The incidence of a major adverse cardiac event (MACE), defined as all-cause death, any myocardial infarction, stroke, revascularisation for de novo lesion(s) or hospitalisation for heart failure was significantly higher in patients with ISR than in those without (45.5% vs. 24.4%, respectively; p<0.01). Specifically, patients with ISR had a higher incidence of all-cause death (16.1% vs. 6.2%, respectively; p<0.01) and revascularisation for de novo lesion(s) (28.6% vs. 16.2%, respectively; p<0.01). Even after adjustment for possible confounders, ISR detected upon RFU-CAG was an independent predictor for MACE (Hazard ratio: 2.13; 95% confidence interval: 1.55 to 2.92: p<0.01) Conclusions: ISR detected upon RFU-CAG were independently associated with an increased MACE, which was mainly driven by an increased incidence of all-cause death and revascularisation for de novo lesion(s).
stent G1 DES = first-generation drug-eluting stent G2 DES = second-generation drug-eluting stent ACEI = angiotensin-converting enzyme inhibitor ARB = angiotensin receptor blocker HRs = hazard ratios 95% CIs = 95% confidence intervals TLR = target lesion revascularisation TVR = target vessel revascularisation
Introduction
Routine follow-up coronary angiography (RFU-CAG) is often performed to assess in-stent restenosis (ISR) after percutaneous coronary intervention (PCI). Although the clinical benefit of RFU-CAG remains a matter of debate due to lack of scientific data, prior studies have shown a reduction in the incidence of post-PCI myocardial infarction (MI) 1, 2) . A matter of concern, however, is physician susceptibility to the so-called oculostenotic reflex, i.e., the tendency for interventionists to perform repeat revascularisation in the absence of symptoms of ischemia when regional stenosis is detected upon RFU-CAG [3] [4] [5] [6] . However, the prognostic impact of restenosis detected upon post-PCI RFU-CAG has been unknown. The aim of this study was to evaluate the significance of ISR detected upon RFU-CAG on long-term outcomes among patients with coronary artery disease treated with PCI with metallic stent(s) for de novo lesion(s).
Methods

STUDY DESIGN AND STUDY PATIENTS
The overall study group comprised 824 patients who had undergone RFU-CAG after successful PCI involving implantation of metallic stent(s) for de novo lesion(s). Our hospital conventionally performed RFU-CAG once about 6 to 9 months after PCI for all patients who had undergone PCI except exceptions. The 824 patients were identified from 917 patients who had undergone PCI at St. Marianna University Hospital between March 2006 and December 2014. Seventy-one of the 917 patients were excluded from the study because they had not received a metallic stent (n=37), PCI had been performed for ISR (n=23), PCI had been performed for bypass graft failure (n=7) or PCI was not successful (n=4). Twenty-two of the 917 patients were excluded because CAG had been performed before RFU-CAG (n=17) or RFU-CAG had not been performed (n=5). We divided the 824 study patients into two groups: those with ISR detected upon RFU-CAG (ISR group, n=112) and those without (non-ISR group, n=712) for comparison of clinical outcomes. The study procedures were approved by the ethics committee at St. Marianna University school of Medicine, Japan (ap-proval number 3904).
DEFINITIONS AND END POINTS
The primary clinical outcome of interest was a major adverse cardiac event (MACE), defined as allcause death, any MI (spontaneous MI, as defined by the Academic Research Consortium) 7) , stroke (neurological dysfunction caused by an ischemic or hemorrhagic cerebrovascular accident requiring hospitalisation with symptoms persisting >24 hours or until death) 8) , revascularisation for de novo lesion(s), or hospitalisation for heart failure.
Cardiac death was defined as death due to a proximate cardiac cause (e.g., MI, low-output heart failure, life-threatening arrhythmia). Chronic kidney disease (CKD) categories G3b-G5 was defined as an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 mm 2 . In the patients with multivessel desease, target vessel location was defined as vessel that initially performed PCI (e.g. acute coronary syndrome; ACS).
Restenosis was defined as diameter stenosis >50% in the in-segment area (including the stented segment and the 5-mm segments proximal and distal to the edges of the stent). ISR was assessed on at least two different angiography projections by three experienced cardiologists, and ISR was diagnosed by consensus.
STATISTICAL ANALYSES
Data are shown as median (and interquartile range), mean±SD, or the number (and percentage) of patients. Variables were compared between the two study groups, and differences were analysed by Student's t test, chi-square test, or Fisher's exact test, as appropriate. Kaplan-Meier curves were drawn for time to MACEs. To determine independent predictors of MACEs, univariate logistic regression models were constructed for the following clinical variables: age at the time of PCI; male sex; body mass index (BMI); hypertension requiring medication; dyslipidemia requiring medication; low-density lipoprotein cholesterol (LDL-C) concentration; high-density lipoprotein cholesterol (HDL-C) concentration; diabetes mellitus (DM) requiring medication; insulin use; HbA1c; CKD categories G3b-G5; hemodialysis; cur-rent smoking; never smoked; brain natriuretic peptide (BNP) concentration; emergency PCI; ACS; acute MI (AMI); use of a bare metal stent (BMS), first-generation drug-eluting stent (G1 DES) or second-generation drug-eluting stent (G2 DES); use of β-blocker, statin, angiotensin-converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB); and restenosis. Variables shown to be significant by univariate analysis were then entered into a multivariable logistic regression model. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were computed for all variables entered into the multivariable regression model. All statistical analysis were performed with SPSS 24.0 for Mac (IBM, Chicago, IL, USA). All tests were two-sided, and p<0.05 was regarded as significant.
Results
RFU-CAG was performed at a median of 187
(182 to 203) days after the index PCI, and the study patients were followed up for a median of 1,323 (709 to 2,130) days after RFU-CAG.
The 112 patients in the ISR group represented 13.6% of the total study patients. Clinical and lesion characteristics of the study patients at the time of PCI are shown per ISR group and non-ISR group on Table 1. Only BMI (23.4±3.0 kg/m 2 vs. 24.3±3.7 kg/m 2 , respectively; p<0.01), use of medication for dyslipidemia (39.3% vs. 59.7%, respectively; p<0.01) and BNP (242±304 ng/mL vs. 142±400 ng/mL, respectively; p<0.01) differed significantly between the two groups. Lesion characteristics did not differ significantly between the two groups, but ACS was more prevalent in the ISR group than in the non-ISR group (64.3% vs. 41.6%, respectively; p<0.01).
Angiographic and procedural details are shown per group in Table 2 . Emergency PCI (61.6% vs. 36.4%, p<0.01), use of manual aspiration (44.6% vs. 27.9%, p<0.01), minimum stent diameter at the target lesion (2.5±0.5 mm vs. 2.8±0.5 mm, p < 0.01) and use of BMS(s) (53.6% vs. 34.3%, p<0.01) were significantly more common in the ISR group than in the non-ISR group. β-blocker use was significantly more common in the ISR group than in the non-ISR group, as shown in Table 3 (75.0% vs. 63.8%, respectively; p=0.02).
Of the 112 patients in the ISR group, 83 (74.1%) underwent PCI for the ISR, 11 (9.8%) underwent bypass surgery, and 18 (16.1%) were treated medically.
MACEs occurred at significantly higher incidence in the ISR group than in the non-ISR group (45.5% vs. 24.4%, p<0.01) (Figure 1) . Specifically, the incidences of all-cause death (16.1% vs. 6.2%, p<0.01) and revascularisation for de novo lesion(s) (28.6% vs. 16.2%, p<0.01) were significantly higher in the ISR group than in the non-ISR group (Figure 2) . As shown in Table 4 , cardiac death (2.6% vs. 1.0%, p=0.14) was similar between the two groups. Multivariable logistic regression analysis showed independent determinants of MACEs to be DM requiring medication (HR: 1.53, 95% CI: 1.17 to 2.00; p=0.02), CKD categories G3b-G5 (HR: 1.94, 95% CI: 1.29 to 2.92; p=0.01), and restenosis (HR: 2.13, 95% CI: 1.55 to 2.92; p<0.01) ( Table 5 ), whereas use of statins was shown to be protective (HR: 0.71, 95% CI: 0.51 to 0.97; p=0.03).
Discussion
In summary, our study yielded three main findings. First, the incidence of MACEs, a study endpoint, was significantly higher in the ISR group than in the non-ISR group, and we believe this was driven mainly by the significantly higher rate at which revascularisation was performed for de novo lesion(s) following RFU-CAG in this group. Second, despite the similarity in the rate of cardiac death, the incidence of all-cause death was significantly higher in the ISR group than in the non-ISR group. Third, restenosis (HR: 2.13, 95% CI: 1.55 to 2.92, p<0.01), DM requiring medication (HR: 1.53, 95% CI: 1.17 to 2.00, p<0.01), and CKD categories G3b-G5 (HR: 1.94, 95% CI: 1.29 to 2.92, p<0.01) were shown to be independent predictors of MACEs, whereas statin use was shown to be protective (HR: 0.71, 95% CI: 0.51 to 0.97; p=0.03). Despite numerous advances regarding evidence-based medical therapy and invasive treatment such as PCI, patients with ISR remain at a high risk for MACEs. Our present findings seem to be useful for identifying those patients requiring more aggressive therapy and management.
THE OCULOSTENOTIC REFLEX PHENOM-ENON
Although we found ISR to be associated with the overall incidence of MACEs, cardiac death, any MI, and hospitalisation for heart failure in particular occurred at similar frequencies between our ISR group and non-ISR group. As noted above, revascularisation for de novo lesion(s) was performed at a higher rate among patients in the ISR group than among patients in the non-ISR group, and this was the result of post-PCI RFU-CAG. Detection of ISR G2 DES = second-generation drug eluting stent. upon RFU-CAG led to subsequent target lesion revascularisation (TLR). That is, the so-called oculostenotic reflex came into play [4] [5] [6] 9) . According to previously reported studies, RFU-CAG might result in the oculostenotic reflex but no improvement in prognosis 10,11) .
LESSONS LEARNED FROM THE PATIENTS IN THE ISR GROUP
We found that the ISR group had a higher incidence of all-cause and non-cardiac mortality compared with the non-ISR group. The frequencies of ACS and use of BMS(s) were significantly greater in our ISR group than in our non-ISR group. In previously reported study of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION), all-cause and non-cardiac 5-year mortality rate was significantly higher in the BMS group than in the everolimus-eluting stent (EES) group, and most common cause of non-cardiac death was cancer 12) . We could hypothesize that background or complications of ACS and use of BMS(s) might have lead to worsened long-term outcomes. This finding is consistent with our results (malignant tu-
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IS REVASCULARISATION FOR ISR NECES-SARY?
Whether medical treatment for ISR increases the incidence and therefore the risk of cardiac death remains controversial. As noted above, among patients in our ISR group, TLR was performed by means of PCI in 74.1% of patients and by means of bypass surgery in 9.8%. We performed an additional analysis by dividing patients into two groups: those in whom ISR was treated medically (n=18) and those in whom ISR was treated by TLR (n=94). The overall incidence of MACEs was similar between these two groups (33.3% vs. 27.4%, p=0.99 by log-rank test), however, the incidence of any MI, a specific MACE, was significantly higher in the first group than in the second group (11.1% vs. 1.7%, p<0.01 by log-rank test). In previously reported substudies of the BAAS (Balloon Angioplasty and Anticoagulation Study) and TAXUS-IV trial, MI occurred at a higher rate among patients in whom RFU-CAG was not performed than among those in whom RFU-CAG was performed, but with no between-group difference in mortality 1, 2, 4) . Previous studies and our current study indicated that revascularisation for ISR might protect against the occurrence of future MI.
With respect to mortality associated with target vessel revascularisation (TVR) in patients with ISR, Cassese et al. showed restenosis at the time of RFU-CAG to be predictive of 4-year mortality in large cohort of patients who had undergone coronary stenting 13) . However, performance of TVR for restenosis was shown not to influence 4-year mortality.
In future studies, a question to explore would be whether TLR or TVR can be optimised to further improve clinical outcomes.
WHAT IS THE POTENTIAL ROLE OF FOL-LOW-UP CAG?
We found that the frequencies of ACS, emergency PCI and use of BMS(s) and the percentage of relatively small minimum stent diameters were significantly greater in ISR group than in non-ISR group. In previous studies, DM, a complex lesion (B2/C), a relatively small reference vessel diameter, multiple stents, relatively long stents and a relatively small minimal stent diameter immediately after stenting have been shown to be predictors of restenosis [13] [14] [15] . Our study data show clearly that follow-up CAG should be seriously considered in patients who present with ACS treated with small BMS(s).
Our study did not aim to examine the effect of RFU-CAG on clinical outcomes, but rather to investigate the significance of ISR detected upon RFU-CAG. A recent guidelines and clinical studies show that follow-up angiography can no longer be recommended as routine strategy in patients with treated with current metal stent(s). However, our results indicated that patients with ISR detected upon RFU-CAG are at high risk for future MACE and require more aggressive therapy and intensive clinical management.
Limitations
Our study was subject to the usual limitations of a retrospective study. In addition, the overall study group was not large and was derived from a single center.
Conclusions
We conclude that ISR detected upon RFU-CAG were independently associated with an increased MACE, which was mainly driven by an increased incidence of all-cause death and revascularisation for de novo lesion(s). The incidences of all-cause death and revascularisation for de novo lesion were significantly higher in the ISR group than in the non-ISR group (16.1% vs. 6.2%, respectively; p <0.01 by log-rank test, 28.6% vs. 16.2%, respectively; p<0.01 by log-rank test). 
